Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line

Life Sciences

Volumn 83, Issue 13-14, 2008, Pages 496-501

  Liu, Fang ^a   Fan, Dongmei ^a   Qi, Jing ^a   Zhu, Huifang ^a   Zhou, Yuan ^a   Yang, Chunzheng ^a   Zhu, Zhenping ^a   Xiong, Dongsheng ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Breast cancer; Breast cancer resistant protein (BCRP); Cytokeratin 8; Multidrug resistance (MDR); ShRNA; Tumor markers

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOKERATIN 8; MITOXANTRONE; SHORT HAIRPIN RNA;

ARTICLE; BREAST CANCER; CELL STRAIN 3T3; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE SILENCING; HUMANS; KERATIN-8; MICE; MITOXANTRONE; NEOPLASM PROTEINS; NIH 3T3 CELLS; PHENOTYPE; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA, UNTRANSLATED; TRANSFECTION;

EID: 52249100134     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.07.017     Document Type: Article

References (32)

1. Anderson J.M., Heindl L.M., Bauman P.A., Ludi C.W., Dalton W.S., and Cress A.E. Cytokeratin expression results in a drug-resistant phenotype to six different chemotherapeutic agents. Clinical Cancer Research 2 1 (1996) 97-105
2. Bailey-Dell K.J., Hassel B., Austin Doyle L., and Ross D.D. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochimca et Biophysica Acta 1520 3 (2001) 234-241
3. Bauman P.A., Dalton W.S., Anderson J.M., and Cress A.E. Expression of cytokeratin confers multiple drug resistance. Proceedings of the National Academy of Sciences of the United States of America 91 12 (1994) 5311-5314
4. Brotherick I., Robson C.N., Browell D.A., Shenfine J., White M.D., Cunliffe W.J., Shenton B.K., Egan M., Webb L.A., Lunt L.G., Young J.R., and Higgs M.J. Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression. Cytometry 32 4 (1998) 301-308
5. Chuthapisith S., Layfield R., Kerr I.D., Hughes C., and Eremin O. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. International Journal of Oncology 30 6 (2007) 1545-1551
6. Cress A.E., and Dalton W.S. Multiple drug resistance and intermediate filaments. Cancer Metastasis Reviews 15 4 (1996) 499-506
7. Cummings J., Ethell B.T., Jardine L., Boyd G., Macpherson J.S., Burchell B., Smyth J.F., and Jodrell D.I. Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Research 63 23 (2003) 8443-8450
8. Fillies T., Werkmeister R., Packeisen J., Brandt B., Morin P., Weingart D., Joos U., and Buerger H. Cytokeratin 8/18 expression indicates a poor prognosis in squamous cell carcinomas of the oral cavity. BMC Cancer (2006) 6-10
9. Fukunaga Y., Bandoh S., Fujita J., Yang Y., Ueda Y., Hojo S., Dohmoto K., Tojo Y., Takahara J., and Ishida T. Expression of cytokeratin 8 in lung cancer cell lines and measurement of serum cytokeratin 8 in lung cancer patients. Lung Cancer 38 1 (2002) 31-38
10. Gires O., Mack B., Rauch J., and Matthias C. CK8 correlates with malignancy in leukoplakia and carcinomas of the head and neck. Biochemical and Biophysical Research Communications 343 1 (2006) 252-259
11. Ji B.S., He L., and Liu G.Q. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Life Sciences 77 18 (2005) 2221-2232
12. Kellner U., Hutchinson L., Seidel A., Lage H., Danks M.K., Dietel M., and Kaufmann S.H. Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of p-glycoprotein. International Journal of Cancer 71 5 (1997) 817-824
13. Kowalski P., Stein U., Scheffer G.L., and Lage H. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Therapy 9 7 (2002) 579-586
14. Kowalski P., Farley K.M., Lage H., and Schneider E. Effective knock down of very high ABCG2 expression by a hammerhead ribozyme. Anticancer Research 24 4 (2004) 2231-2235
15. Lage H., and Dietel M. Cloning and characterization of cDNAs encoding a protein with high homology to rat intestinal development protein OCI-5. Gene 188 2 (1997) 151-156
16. Li L., Pan Q.R., Sun M., Lu Q.H., and Hu X. Dibenzocyclooctadiene lignans - a class of novel inhibitors of multidrug resistance-associated protein. Life Sciences 80 8 (2007) 741-748
17. Li W.T., Zhou G.Y., Song X.R., Chi W.L., Ren R.M., and Wang X.W. Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference. Neoplasma 52 3 (2005) 219-224
18. Longley D.B., and Johnston P.G. Molecular mechanisms of drug resistance. The Journal of Pathology 205 2 (2005) 275-292
19. Moran E., Cleary I., Larkin A.M., Amhlaoibh R.N., Masterson A., Scheper R.J., Izquierdo M.A., Center M., O'Sullivan F., and Clynes M. Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42. European Journal of Cancer 33 4 (1997) 652-660
20. Nakagawa M., Schneider E., Dixon K.H., Horton J., Kelley K., Morrow C., and Cowan K.H. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdrl) overexpression in mitoxantrone-resistant MCF-7 breast cancer cells. Cancer Research 52 22 (1992) 6175-6181
21. O'Driscoll L., and Clynes M. Molecular markers of multiple drug resistance in breast cancer. Chemotherapy 52 3 (2006) 125-129
22. Oshima R.G., Baribault H., and Caulfn C. Oncogenic regulation and function of keratins 8 and 18. Cancer Metastasis Reviews 15 4 (1996) 445-471
23. Papazisis K.T., Geromichalos G.D., Dimitriadis K.A., and Kortsaris A.H. Optimization of the sulforhodamine B colorimetric assay. Journal of Immunological Methods 208 2 (1997) 151-158
24. Paramio J.M., and Jorcano J.L. Beyond structure: do intermediate filaments modulate cell signalling?. Bioessays 24 9 (2002) 836-844
25. Priebsch A., Rompe F., Tonies H., Kowalski P., Surowiak P., Stege A., Materna V., and Lage H. Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells. Oligonucleotides 16 (2006) 263-274
26. Raul U., Sawant S., Dange P., Kalraiya R., Ingle A., and Vaidya M. Implication of cytokeratin 8/18 filament formation in stratified epithelial cells: induction of transformed phenotype. International Journal of Cancer 111 5 (2004) 662-668
27. Roberti A., La Sala D., and Cinti C. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. Journal of Cellular Physiology 207 3 (2006) 571-581
28. Ross D.D., Yang W.D., Abruzzo L.V., Dalton W.S., Schneider E., Lage H., Dietel M., Greenberger L., Cole S.P., and Doyle L.A. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. Journal of the National Cancer Institute 91 5 (1999) 429-433
29. Stavrovskaya A.A. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 65 1 (2000) 95-106
30. Szakács G., Paterson J.K., Ludwig J.A., Booth-Genthe C., and Gottesman M.M. Targeting multidrug resistance in cancer. Nature Reviews. Drug Discovery 5 3 (2006) 219-234
31. Yang C.J., Horton J.K., Cowan K.H., and Schneider E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Research 55 18 (1995) 4004-4009
32. Yu S., Chen T., Tseng S., and Chen Y. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochemical and Biophysical Research Communications 358 1 (2007) 79-84